NEXTECH INVEST LTD
Q1 2022 Form 13-F
ZURICH
CIK 0001911010
· CRD 322629
· Exempt reporting adviser
$350.3M Reported Value Total
Exempt Reporting Adviser
nextechinvest.com
Source: Form ADV filed 2026-03-27
Reported value
$350.3M
Quarter over quarter
-24.9%
Holdings
14
Top-10 concentration
90.5%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Marco Weibel
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2022 13F record
Q1 2022 13F filing summary
| Period of report | March 31, 2022 |
|---|---|
| Filed | May 16, 2022 |
| Form | 13F-HR |
| Reported value | $350.3M |
| Positions | 14 |
| Change in reported value | -7.7% |
| New positions | 3 |
| Exited positions | 0 |
| Position turnover | 21.4% |
| Top-10 concentration | 90.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2024 13F
Filed Feb 14, 2025
|
15 | $616.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $712.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $594.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $630.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
11 | $536.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
14 | $330.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
13 | $294.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
12 | $239.6M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
14 | $251.4M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $309.6M |
|
Q2 2022 13F
Filed Aug 1, 2022
|
14 | $296.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
14 | $350.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
11 | $379.6M |
Top 14 holdings · Q1 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | $100.5M | 28.69% |
| 2 | EQRX EQRX INC | $54.1M | 15.45% |
| 3 | KNTE KINNATE BIOPHARMA INC | $33.9M | 9.67% |
| 4 | PMVP PMV PHARMACEUTICALS INC | $28.9M | 8.24% |
| 5 | TYRA TYRA BIOSCIENCES INC | $26.9M | 7.69% |
| 6 | ARVN ARVINAS INC | $19.3M | 5.52% |
| 7 | MRTX MIRATI THERAPEUTICS INC | $14.2M | 4.07% |
| 8 | RLAY RELAY THERAPEUTICS INC | $14.2M | 4.06% |
| 9 | CGEM CULLINAN ONCOLOGY INC | $12.8M | 3.65% |
| 10 | BPMC BLUEPRINT MEDICINES CORP | $12.0M | 3.43% |
| 11 | KRON KRONOS BIO INC | $10.5M | 3.0% |
| 12 | CCCC C4 THERAPEUTICS INC | $9.1M | 2.6% |
| 13 | THRX THESEUS PHARMACEUTICALS INC | $7.0M | 2.01% |
| 14 | SPRY SILVERBACK THERAPEUTICS INC | $6.7M | 1.91% |
Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.